## UTHR: United Therapeutics Corporation - XLV: Healthcare

### Executive Summary

VALUE thesis: PEG 1.44 indicates fundamental undervaluation. Quality metrics strong (ROE 20%, ROA 13%).

- **Horizon:** 20-60 days (position)
- **Risk Profile:** Lower - fundamental undervaluation
- **Stop Type:** Fixed 2xATR ($490.21)
- **If Wrong:** Exit if fundamentals deteriorate or stop hit
- **Invalidation:** PEG > 1.5 or earnings miss

### News

- **Articles:** 3
- **Sentiment:** Neutral (Bullish: 0, Bearish: 0)

**1. Wedge Capital Management L L P NC Reduces Position in United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251221T120833 | Neutral | Relevance: 100%
- Wedge Capital Management L L P NC notably reduced its stake in United Therapeutics Corporation by 30.6% in the third quarter, selling 29,292 shares. This reduction, along with significant insider selling by executives like CEO Martine Rothblatt, suggests a potential near-term headwind for investor sentiment. Despite this, analysts largely maintain a "Moderate Buy" rating with an average target price of $505, with some firms raising targets up to $575.

**2. Signal Advisors Wealth LLC Sells 2,744 Shares of United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251221T110833 | Neutral | Relevance: 100%
- Signal Advisors Wealth LLC reduced its stake in United Therapeutics Corporation by 51.4%, selling 2,744 shares and retaining 2,595 shares valued at approximately $1.09 million. This sale follows significant insider selling recently, though analysts maintain a "Moderate Buy" consensus rating with a target price of $505. The company reported an EPS beat for the last quarter despite slightly missing revenue estimates.

**3. Assenagon Asset Management S.A. Sells 13,202 Shares of United Therapeutics Corporation $UTHR**
- Source: MarketBeat | 20251221T080833 | Somewhat-Bearish | Relevance: 100%
- Assenagon Asset Management S.A. has reduced its stake in United Therapeutics Corporation (NASDAQ:UTHR) by 38.8%, selling 13,202 shares and retaining 20,804 shares valued at $8.72 million. Despite recent heavy insider selling, including significant reductions by the COO and CEO, analysts maintain a "Moderate Buy" rating with a consensus price target of $505. The stock has seen a 1-year low of $266.98 and a high of $518.61, with a current market cap of $22.27 billion.

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 24 ($15.66M) |
| Sells | 65 ($31.65M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 48.7% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 4 / 6 |

**Top Holders:**
- Blackrock Inc.: 12.4% (+0.4%)
- Vanguard Group Inc: 10.3% (-0.7%)
- Renaissance Technolo: 5.1% (+2.6%)
- Avoro Capital Adviso: 4.7% (-14.7%)
- State Street Corpora: 4.5% (-11.3%)

### Key Risks

1. Heavy insider selling: $32M sold (65 transactions in 90 days).
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- Broader market risk-on sentiment could lift quality names.
- Year-end positioning and window dressing may support price.

### Fundamentals

PEG ratio 1.44 suggests fair value with growth premium. Forward P/E 18.0x stretched relative to 5% growth. Quality metrics strong (ROA 13%, margin 41%). Balance sheet: strong liquidity (6.4x), low leverage (D/E 0.12). Insider selling cluster ($31.6M in 90 days), potential headwind. Institutional flow bullish (4 buying vs 6 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $23.2B |
| Beta | 0.86 |
| 52W Range | $266.98 - $519.65 |
| Short Interest | 5.5% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.44 |
| Forward P/E | 18.0 |
| Current P/E | 19.0 |
| YoY Growth | 5.1% |
| EPS Direction | STABLE |

### Technicals

MRS_20 improving modestly (+0.5% over 5 days). Currently in lower STRENGTH zone (4.0-10.0%), cross-sectional ranking at 79th percentile. MRS_5 (-0.6%) diverging from MRS_20 - short-term weakness emerging. AM_20 at 4.7% shows strong absolute momentum above own 20MA. Outperforming sector by 4.2pp, stock-specific strength. Full SMA alignment bullish (above 20/50/200 SMAs). MACD histogram positive (1.62), confirming momentum. Elevated volume (2.0x 20MA), institutional activity likely. OFD pattern: -SLN (Support test).

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | 4.03% (CS: 80) | Strong |
| RSI_14 | 69.9 | Neutral |
| MACD Histogram | 1.62 | Bullish |
| vs SMA20 | 1.047x | Above |
| vs SMA50 | 1.107x | Above |
| vs SMA200 | 1.430x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** VALUE

### Trade Setup

- **Entry:** $513.79
- **Stop Loss:** $490.21 (4.6% risk)
- **Target:** $560.95 (R:R method)
- **Risk/Reward:** 2.00:1
- **Target Reasoning:** VALUE thesis targets 2.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 50
- **Position Value:** $25,689.50
- **Portfolio %:** 25.69%
- **Risk Dollars:** $1,200.00
- **Risk Per Trade:** 1.20%
- **Modifiers:** L1 120% | L2 100% | Combined 1.20x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.20x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with improving risk appetite. VIX decline to 52-week lows and moderate breadth recovery suggest calming conditions, though narrow participation indicates selectivity remains key. Positive earnings momentum and AI adoption themes provide fundamental support for quality growth names.*

### Earnings

**Next:** 2026-02-25 (Est: $6.88)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $6.96 | $7.16 | +2.9% |
| 2025Q2 | $6.94 | $6.41 | -7.6% |
| 2025Q1 | $6.28 | $6.63 | +5.6% |
| 2024Q4 | $6.27 | $6.19 | -1.2% |

---
*RULE-based L3 | 2026-01-06 16:38 | MRS_20*